Limitations of FibroScan (Transient Elastography)
FibroScan has significant technical and clinical limitations that can lead to failed measurements in up to 29% of patients and falsely elevated readings in conditions causing hepatic inflammation, cholestasis, or vascular congestion.
Technical Failure and Unreliable Measurements
FibroScan fails or produces unreliable results in approximately 29% of patients 1. The highest risk patients are:
- Women over 50 years with BMI >27.7 kg/m², weight >77 kg, and height <162 cm experience failure rates up to 58.5% 1
- Obese patients (BMI ≥30 kg/m²) have failure rates of 49.5% 1
- Narrow intercostal spaces and substantial thoracic fat further reduce applicability 2, 3
The XL probe improves success in obese patients but requires different cutoff values (approximately 1.2-1.3 kPa lower than M probe) 4.
Clinical Confounders That Falsely Elevate Liver Stiffness
Critical pitfall: Liver stiffness measures tissue elasticity, not just fibrosis. Multiple conditions cause falsely elevated readings 5, 6:
Inflammation and Hepatitis
- ALT elevation is a major confounder in chronic hepatitis B; higher cutoff values must be used when ALT is elevated up to 5× upper limit of normal 4
- ALT flares can produce falsely high readings in the cirrhotic range 4
- Acute liver damage frequently yields pathologically high values suggesting cirrhosis even when none exists; FibroScan is unsuitable for detecting cirrhosis in acute hepatitis 7
Other Confounders
- Obstructive cholestasis artificially increases stiffness 5, 6
- Venous congestion (e.g., heart failure) elevates readings 5, 6
- Recent food intake: Requires minimum 3 hours fasting (not 2 hours as previously recommended) 6
- Exercise transiently increases values 6
Diagnostic Accuracy Limitations
Poor Discrimination Between Adjacent Fibrosis Stages
- Wide variation in stiffness values within the same fibrosis stage with overlap between adjacent stages 2
- Suboptimal accuracy for diagnosing mild-to-moderate fibrosis (F1-F2) 6
- Cannot adequately discriminate between adjacent fibrosis stages 6
Stage-Specific Performance
According to the 2025 AASLD systematic review 5:
- F2-4 detection: sensitivity 51-95%, specificity 36-100%
- F3-4 detection: sensitivity 70-100%, specificity 74-100%
- F4 detection: sensitivity 60-100%, specificity 67-99%
Accuracy improves for advanced fibrosis but remains imperfect even for cirrhosis detection.
What FibroScan Cannot Assess
- Subclinical hepatic inflammation and ballooning 6
- Exact severity of portal hypertension in compensated advanced chronic liver disease 6
- Cirrhosis nodule size affects stiffness values 2
Disease-Specific Considerations
Cutoff values vary by etiology and differ between adults and children 5. Using universal cutoffs across mixed etiologies reduces accuracy. Disease-specific thresholds are necessary for optimal classification 5.
Practical Approach to Minimize Errors
- Ensure 3-hour fasting before measurement 6
- Exclude acute conditions: active hepatitis flare, cholestasis, heart failure 5, 6, 7
- Use XL probe in obese patients with appropriate adjusted cutoffs 4
- Adjust interpretation for elevated ALT in hepatitis B 4
- Combine with other non-invasive tests (e.g., FibroTest) to improve accuracy 2
- Interpret results within clinical context including laboratory values, imaging, and physical examination 3
When to Avoid FibroScan
- Acute liver damage or ALT flare 7
- Active cholestasis 5, 6
- Decompensated heart failure 5, 6
- Within 3 hours of eating 6
- Immediately post-exercise 6
Bottom line: FibroScan is a useful screening tool for advanced fibrosis and cirrhosis in stable chronic liver disease, but requires careful patient selection, proper technique, exclusion of confounders, and integration with clinical data to avoid misdiagnosis.